Treatment of small cell bronchogenic carcinoma with VM-26.
VM-26 is active in small cell bronchogenic carcinoma even in patients resistant to previous chemotherapy. The overall response rate was 28%, with a response rate of 29% in patients resistant to previous chemotherapy. This response rate is similar to that obtained with other single agents including Adriamycin, vincristine, cyclophosphamide, and procarbazine. The mild subjective and objective toxic effects of the drug make it a potentially useful agent in the treatment of this tumor.
D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D005260:Female; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012075:Remission, Spontaneous; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*
D013713:Teniposide; D011034:Podophyllotoxin